Allergan Plc (AGN) 254.32 $AGN
Allergan plc Completes Divestiture of Global Generics Business to Teva Pharmaceuticals
PR Newswire - 29 mins ago
Allergan plc (NYSE: AGN) today announced that it has completed the divestiture of its global generic pharmaceuticals business to Teva Pharmaceutical Industries Ltd. Allergan has received $33.4 billion in cash and 100.3 million shares of Teva stock valued at $5.4 billion based on the opening price of $53.39 for Teva Pharmaceutical Industries Ltd. shares on August 2, 2016. These shares are subject to a twelve month holding period post-close of the transaction.
AGN: 254.32 (-0.54), TEVA: 53.19 (-0.42)
California Life Sciences Association Announces Expansion of Board of Directors
BusinessWire - Tue Aug 02, 7:00AM CDT
California Life Sciences Association (CLSA) today announced an expansion of its board of directors, adding two new members. Alex Kelly, Executive Vice President, Chief Communications Officer, Allergan and Jens H. Vogel, Ph.D., President & CEO, Boehringer Ingelheim Fremont Inc., have joined the CLSA board. CLSA is the nation's largest statewide life sciences public policy advocacy and business solutions organization serving biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors, and service providers across the state of California.
AGN: 254.32 (-0.54)
Teva (TEVA): Stock Likely to Beat on Earnings in Q2 Again?
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 6:06AM CDT
Our proven model shows that Teva (TEVA) is likely to beat earnings this quarter because it has the right combination of two key ingredients.
AGN: 254.32 (-0.54), RPTP: 5.82 (-0.25), TECH: 112.53 (-1.25), TEVA: 53.19 (-0.42)
RECORDATI AND RICHTER SIGNED A LICENSE AGREEMENT FOR MARKETING CARIPRAZINE IN WESTERN EUROPE
GlobeNewswire - Tue Aug 02, 1:14AM CDT
Recordati and Gedeon Richter today announced the signing of an exclusive license agreement to commercialize cariprazine, a novel atypical antipsychotic in Western Europe and in Algeria, in Tunisia and in Turkey.
AGN: 254.32 (-0.54)
Bioniz Therapeutics Closes Series A Financing and Appoints David Pyott as Chairman of the Board of Directors
PR Newswire - Mon Aug 01, 6:00AM CDT
Bioniz Therapeutics, Inc., a biopharmaceutical company leading the discovery and development of first-in-class peptide therapeutics that selectively and simultaneously inhibit multiple cytokines to treat immuno-inflammatory diseases and cancer, announced today that it has raised $13 million in its Series A funding. The investment syndicate was co-led by Takeda, via its corporate venture arm Takeda Ventures Inc., and Dr. David Pyott, and also includes investments from Mr. Joe Kiani, and Cota Capital. The Company also announced that it has appointed Dr. David Pyott as Chairman of the Board of Directors, effective immediately. Dr. Pyott is the past Chairman and Chief Executive Officer of Allergan Inc. (AGN). In connection with the financing, Ilan Zipkin Ph.D., Senior Investment Director, Takeda Ventures, and Joe Kiani, Chairman and CEO of medical device company Masimo Corporation (MASI), have also joined the Company's Board of Directors.
AGN: 254.32 (-0.54), MASI: 52.57 (-0.36)
Global Anti-aging Market Report 2015-2019 - Analysis, Technologies & Forecasts - Key Vendors: Allergan, Coty, Lumenis - Research and Markets
BusinessWire - Fri Jul 29, 5:46AM CDT
Research and Markets has announced the addition of the "Anti-aging Market: Global Industry Analysis and Opportunity Assessment, 2015-2019" report to their offering.
AGN: 254.32 (-0.54)
Teva expect to close $40.5B Allergan generic deal next week
AP - Wed Jul 27, 3:31PM CDT
NEW YORK (AP) — Israeli drugmaker Teva, the largest generic drug company in the world, said Wednesday it expects to complete its $40.5 billion purchase of the generic drug business of competitor Allergan next week after federal regulators approved the deal.
AGN: 254.32 (-0.54), TEVA: 53.19 (-0.42)
Teva Receives Clearance from the U.S. Federal Trade Commission for Actavis Generics Acquisition
BusinessWire - Wed Jul 27, 1:36PM CDT
--Added Capabilities, Assets and Talent Advance Teva's Focus on Patient Needs and Providing Affordable Generic Products to Patients at Every Stage of Life Worldwide
AGN: 254.32 (-0.54), TEVA: 53.19 (-0.42)
After Yesterday's Rally of 1.47% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jul 27, 11:47AM CDT
Allergan (NYSE:AGN) traded in a range yesterday that spanned from a low of $249.00 to a high of $255.48. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $250.75 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AGN: 254.32 (-0.54)
Hologic (HOLX) Q3 Earnings: A Surprise in the Cards?
Zacks Equity Research - Zacks Investment Research - Tue Jul 19, 6:31AM CDT
Hologic (HOLX) has a Zacks Rank #2 (Buy) which along with a 0.00 % ESP makes surprise prediction difficult.
AGN: 254.32 (-0.54), LH: 138.58 (-1.05), BMY: 75.13 (-1.06), HOLX: 39.13 (+0.15)
Illumina (ILMN) to Report Q2 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Tue Jul 19, 6:08AM CDT
Illumina (ILMN) has a Zacks Rank #4 (Sell), which along with an ESP of 0.00% makes surprise prediction difficult.
AGN: 254.32 (-0.54), LH: 138.58 (-1.05), ILMN: 165.02 (-5.63), BMY: 75.13 (-1.06)
Edwards Lifesciences (EW) Q2 Earnings: Will It Be a Miss?
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 3:56PM CDT
Edwards (EW) has a Zacks Rank #4 (Sell), which along with a negative ESP of -1.43% makes surprise prediction difficult.
AGN: 254.32 (-0.54), EW: 113.05 (-1.18), LH: 138.58 (-1.05), BMY: 75.13 (-1.06)
Top 7 Research Reports for July 15, 2016
Sheraz Mian - Zacks Investment Research - Fri Jul 15, 1:10PM CDT
Top 7 Research Reports for July 15, 2016
AGN: 254.32 (-0.54), DFS: 55.39 (-0.95), XEL: 43.73 (-0.21), BA: 131.59 (-1.62), CL: 74.70 (-0.41), K: 81.71 (-0.66)
Market Updates on Drugs - Generic Equities -- Mylan, Horizon Pharma, Allergan, and Diplomat Pharmacy
PR Newswire - Fri Jul 15, 6:30AM CDT
On Thursday, July 14, 2016, the NASDAQ Composite ended the trading session at 5,034.06, up 0.57%; the Dow Jones Industrial Average edged 0.73% higher, to finish at 18,506.41; and the S&P 500 closed at 2,163.75, up 0.53%. The gains were broad based as eight out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), Allergan PLC (NYSE: AGN), and Diplomat Pharmacy Inc. (NYSE: DPLO). Learn more about these stocks by accessing their free notes at:
AGN: 254.32 (-0.54), DPLO: 35.84 (+0.12), HZNP: 19.26 (+0.37), MYL: 46.20 (-0.54)
Teva (TEVA) Provides 2016-2019 Outlook, Shares Gain
Arpita Dutt - Zacks Investment Research - Thu Jul 14, 7:10AM CDT
Teva (TEVA) provided its preliminary outlook for 2016-2019 and expects the Actavis Generics acquisition to go through anytime soon.
AGN: 254.32 (-0.54), MYL: 46.20 (-0.54), TEVA: 53.19 (-0.42), RDY: 44.19 (-0.31)
Asian shares mixed in cautious trading
By TERESA CEROJANO - AP - Wed Jul 13, 11:01PM CDT
MANILA, Philippines (AP) — Asian shares were mixed Thursday in cautious trading ahead of a Bank of England meeting, Friday's release of China's GDP data, and as investors digest new British Prime Minister Theresa May's Cabinet.
AGN: 254.32 (-0.54)
Michaels and Hess slide, Teva and JetBlue trade higher
AP - Wed Jul 13, 3:27PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Wednesday:
AGN: 254.32 (-0.54), HES: 50.50 (-0.73), JUNO: 30.22 (-0.64), TEVA: 53.19 (-0.42), JBLU: 17.21 (-0.99), AET: 115.91 (+1.46), AIR: 23.72 (-0.28)
Markets Right Now: US stock indexes edge mostly higher
AP - Wed Jul 13, 3:19PM CDT
NEW YORK (AP) — The latest on developments in global financial markets (all times local):
AGN: 254.32 (-0.54)
Why are Allergan (AGN) and Teva Pharma (TEVA) Stocks Up Today?
Madeleine Johnson - Zacks Investment Research - Wed Jul 13, 10:39AM CDT
On Wednesday, shares of Allergan (AGN) and Teva Pharmaceuticals (TEVA) are both on the rise, up around 2% and 3%, respectively, in morning trading after Teva CEO Erez Vigodman said it expects its $40.5 billion acquisition of Allergan's generics business to close any day.
AGN: 254.32 (-0.54), TEVA: 53.19 (-0.42)
Allergan plc Completes Divestiture of Global Generics Business to Teva Pharmaceuticals
PR Newswire - 29 mins ago
Allergan plc (NYSE: AGN) today announced that it has completed the divestiture of its global generic pharmaceuticals business to Teva Pharmaceutical Industries Ltd. Allergan has received $33.4 billion in cash and 100.3 million shares of Teva stock valued at $5.4 billion based on the opening price of $53.39 for Teva Pharmaceutical Industries Ltd. shares on August 2, 2016. These shares are subject to a twelve month holding period post-close of the transaction.
AGN: 254.32 (-0.54), TEVA: 53.19 (-0.42)
California Life Sciences Association Announces Expansion of Board of Directors
BusinessWire - Tue Aug 02, 7:00AM CDT
California Life Sciences Association (CLSA) today announced an expansion of its board of directors, adding two new members. Alex Kelly, Executive Vice President, Chief Communications Officer, Allergan and Jens H. Vogel, Ph.D., President & CEO, Boehringer Ingelheim Fremont Inc., have joined the CLSA board. CLSA is the nation's largest statewide life sciences public policy advocacy and business solutions organization serving biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors, and service providers across the state of California.
AGN: 254.32 (-0.54)
Teva (TEVA): Stock Likely to Beat on Earnings in Q2 Again?
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 6:06AM CDT
Our proven model shows that Teva (TEVA) is likely to beat earnings this quarter because it has the right combination of two key ingredients.
AGN: 254.32 (-0.54), RPTP: 5.82 (-0.25), TECH: 112.53 (-1.25), TEVA: 53.19 (-0.42)
RECORDATI AND RICHTER SIGNED A LICENSE AGREEMENT FOR MARKETING CARIPRAZINE IN WESTERN EUROPE
GlobeNewswire - Tue Aug 02, 1:14AM CDT
Recordati and Gedeon Richter today announced the signing of an exclusive license agreement to commercialize cariprazine, a novel atypical antipsychotic in Western Europe and in Algeria, in Tunisia and in Turkey.
AGN: 254.32 (-0.54)
Bioniz Therapeutics Closes Series A Financing and Appoints David Pyott as Chairman of the Board of Directors
PR Newswire - Mon Aug 01, 6:00AM CDT
Bioniz Therapeutics, Inc., a biopharmaceutical company leading the discovery and development of first-in-class peptide therapeutics that selectively and simultaneously inhibit multiple cytokines to treat immuno-inflammatory diseases and cancer, announced today that it has raised $13 million in its Series A funding. The investment syndicate was co-led by Takeda, via its corporate venture arm Takeda Ventures Inc., and Dr. David Pyott, and also includes investments from Mr. Joe Kiani, and Cota Capital. The Company also announced that it has appointed Dr. David Pyott as Chairman of the Board of Directors, effective immediately. Dr. Pyott is the past Chairman and Chief Executive Officer of Allergan Inc. (AGN). In connection with the financing, Ilan Zipkin Ph.D., Senior Investment Director, Takeda Ventures, and Joe Kiani, Chairman and CEO of medical device company Masimo Corporation (MASI), have also joined the Company's Board of Directors.
AGN: 254.32 (-0.54), MASI: 52.57 (-0.36)
Global Anti-aging Market Report 2015-2019 - Analysis, Technologies & Forecasts - Key Vendors: Allergan, Coty, Lumenis - Research and Markets
BusinessWire - Fri Jul 29, 5:46AM CDT
Research and Markets has announced the addition of the "Anti-aging Market: Global Industry Analysis and Opportunity Assessment, 2015-2019" report to their offering.
AGN: 254.32 (-0.54)
Teva expect to close $40.5B Allergan generic deal next week
AP - Wed Jul 27, 3:31PM CDT
NEW YORK (AP) — Israeli drugmaker Teva, the largest generic drug company in the world, said Wednesday it expects to complete its $40.5 billion purchase of the generic drug business of competitor Allergan next week after federal regulators approved the deal.
AGN: 254.32 (-0.54), TEVA: 53.19 (-0.42)
Teva Receives Clearance from the U.S. Federal Trade Commission for Actavis Generics Acquisition
BusinessWire - Wed Jul 27, 1:36PM CDT
--Added Capabilities, Assets and Talent Advance Teva's Focus on Patient Needs and Providing Affordable Generic Products to Patients at Every Stage of Life Worldwide
AGN: 254.32 (-0.54), TEVA: 53.19 (-0.42)
After Yesterday's Rally of 1.47% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jul 27, 11:47AM CDT
Allergan (NYSE:AGN) traded in a range yesterday that spanned from a low of $249.00 to a high of $255.48. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $250.75 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AGN: 254.32 (-0.54)
Hologic (HOLX) Q3 Earnings: A Surprise in the Cards?
Zacks Equity Research - Zacks Investment Research - Tue Jul 19, 6:31AM CDT
Hologic (HOLX) has a Zacks Rank #2 (Buy) which along with a 0.00 % ESP makes surprise prediction difficult.
AGN: 254.32 (-0.54), LH: 138.58 (-1.05), BMY: 75.13 (-1.06), HOLX: 39.13 (+0.15)
Illumina (ILMN) to Report Q2 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Tue Jul 19, 6:08AM CDT
Illumina (ILMN) has a Zacks Rank #4 (Sell), which along with an ESP of 0.00% makes surprise prediction difficult.
AGN: 254.32 (-0.54), LH: 138.58 (-1.05), ILMN: 165.02 (-5.63), BMY: 75.13 (-1.06)
Edwards Lifesciences (EW) Q2 Earnings: Will It Be a Miss?
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 3:56PM CDT
Edwards (EW) has a Zacks Rank #4 (Sell), which along with a negative ESP of -1.43% makes surprise prediction difficult.
AGN: 254.32 (-0.54), EW: 113.05 (-1.18), LH: 138.58 (-1.05), BMY: 75.13 (-1.06)
Top 7 Research Reports for July 15, 2016
Sheraz Mian - Zacks Investment Research - Fri Jul 15, 1:10PM CDT
Top 7 Research Reports for July 15, 2016
AGN: 254.32 (-0.54), DFS: 55.39 (-0.95), XEL: 43.73 (-0.21), BA: 131.59 (-1.62), CL: 74.70 (-0.41), K: 81.71 (-0.66)
Market Updates on Drugs - Generic Equities -- Mylan, Horizon Pharma, Allergan, and Diplomat Pharmacy
PR Newswire - Fri Jul 15, 6:30AM CDT
On Thursday, July 14, 2016, the NASDAQ Composite ended the trading session at 5,034.06, up 0.57%; the Dow Jones Industrial Average edged 0.73% higher, to finish at 18,506.41; and the S&P 500 closed at 2,163.75, up 0.53%. The gains were broad based as eight out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), Allergan PLC (NYSE: AGN), and Diplomat Pharmacy Inc. (NYSE: DPLO). Learn more about these stocks by accessing their free notes at:
AGN: 254.32 (-0.54), DPLO: 35.84 (+0.12), HZNP: 19.26 (+0.37), MYL: 46.20 (-0.54)
Teva (TEVA) Provides 2016-2019 Outlook, Shares Gain
Arpita Dutt - Zacks Investment Research - Thu Jul 14, 7:10AM CDT
Teva (TEVA) provided its preliminary outlook for 2016-2019 and expects the Actavis Generics acquisition to go through anytime soon.
AGN: 254.32 (-0.54), MYL: 46.20 (-0.54), TEVA: 53.19 (-0.42), RDY: 44.19 (-0.31)
Asian shares mixed in cautious trading
By TERESA CEROJANO - AP - Wed Jul 13, 11:01PM CDT
MANILA, Philippines (AP) — Asian shares were mixed Thursday in cautious trading ahead of a Bank of England meeting, Friday's release of China's GDP data, and as investors digest new British Prime Minister Theresa May's Cabinet.
AGN: 254.32 (-0.54)
Michaels and Hess slide, Teva and JetBlue trade higher
AP - Wed Jul 13, 3:27PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Wednesday:
AGN: 254.32 (-0.54), HES: 50.50 (-0.73), JUNO: 30.22 (-0.64), TEVA: 53.19 (-0.42), JBLU: 17.21 (-0.99), AET: 115.91 (+1.46), AIR: 23.72 (-0.28)
Markets Right Now: US stock indexes edge mostly higher
AP - Wed Jul 13, 3:19PM CDT
NEW YORK (AP) — The latest on developments in global financial markets (all times local):
AGN: 254.32 (-0.54)
Why are Allergan (AGN) and Teva Pharma (TEVA) Stocks Up Today?
Madeleine Johnson - Zacks Investment Research - Wed Jul 13, 10:39AM CDT
On Wednesday, shares of Allergan (AGN) and Teva Pharmaceuticals (TEVA) are both on the rise, up around 2% and 3%, respectively, in morning trading after Teva CEO Erez Vigodman said it expects its $40.5 billion acquisition of Allergan's generics business to close any day.
AGN: 254.32 (-0.54), TEVA: 53.19 (-0.42)
